Peer-reviewed veterinary case report
Cats with lymphoma treated weekly with COP chemotherapy protocol
By Waite, Angharad H K et al.Ā·Published in Journal of the American Veterinary Medical AssociationĀ·2013Ā·Department of Clinical Studies, United StatesĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Lymphoma in cats treated with a weekly cyclophosphamide-, vincristine-, and prednisone-based protocol: 114 cases (1998-2008).
- Species:
- cat
Plain-English summary
A group of 114 cats diagnosed with lymphoma (a type of cancer) received a chemotherapy treatment plan that included cyclophosphamide, vincristine, and prednisone. After the first round of treatment, about 47% of the cats showed a positive response, which was linked to longer survival times. On average, cats that responded to treatment lived significantly longer, with a median overall survival of 591 days compared to just 73 days for those that did not respond. This suggests that how well a cat responds to the first cycle of chemotherapy can help guide future treatment decisions.
People also search for: cat lymphoma treatment Ā· chemotherapy for cats Ā· lymphoma survival rates in cats
Abstract
OBJECTIVE: To evaluate the clinical response rate, progression-free survival time, overall survival time, and possible prognostic factors associated with a cyclophosphamide-, vincristine-, and prednisone (COP)-based chemotherapy protocol in cats with lymphoma. DESIGN: Retrospective case series. ANIMALS: 114 cats with lymphoma. PROCEDURES: Medical records of cats receiving a weekly COP-based chemotherapy protocol from 1998 to 2008 at the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania were evaluated for information regarding signalment, anatomic site of involvement, cell morphology, treatment, and outcome. Retroviral status, baseline weight, substage, anatomic location, dose delays, dose reductions, and response to treatment were evaluated for prognostic importance. RESULTS: The majority of cases (94 [82.4%]) were substage b, and the most common anatomic site was the gastrointestinal tract (57 [50%]). Clinical response rate after the first chemotherapy cycle was 47.4%. Response to treatment was significantly associated with progression-free survival time and overall survival time, whereas substage was significantly associated with progression-free survival time. The median progression-free survival time and overall survival time were 65.5 and 108 days, respectively. Compared with nonresponders, responders had significantly longer median progression-free survival time (364 vs 31 days) and median overall survival time (591 vs 73 days). CONCLUSIONS AND CLINICAL RELEVANCE: Clinical response after 1 cycle of COP-based chemotherapy was predictive for progression-free survival time and overall survival time in cats with lymphoma; therefore, response after 1 cycle of chemotherapy could be used to guide decisions about further treatment. No new prognostic factors were identified.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23547674/